NCT00686751|CompletedPhase 2DMC
Immune Effects of Vitamin D in Hemodialysis Patients
Immunomodulatory Effects of Vitamin D in Chronic Hemodialysis Patients
Loading search results
Sponsor study identifier
interventional
20
1 country
3
Study Start
December 2004
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
September 2007
Actual (reported)Study Completion
September 2007
Actual (reported)The purpose of this study to examine whether vitamin D can reduce the activation of the immune system during dialysis. When activated, the immune cells release certain substances, called cytokines, which can be measured from small blood samples. We want to study to what degree the immune system is activated during a regular dialysis treatment and whether the time point of vitamin D administration, either right before the start or right at the end of a dialysis treatment, has an impact on the activation of the immune system.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 2007
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 2004
Date type not reportedThis date has not been verified as actual or estimated.
September 2007
Actual (reported)September 2007
Actual (reported)May 27, 2008
Actual (reported)May 30, 2008
Actual (reported)measurement of pro- and anti-inflammatory cytokines and inflammatory markers
first and second HD treatments for the 4 weeks of the study
serum calcium level
24 hours after termination of second HD treatment in week 3 of study
serum phosphate level
24 hours after termination of second HD treatment in week 3 of study
There is only one arm in this study. Each subject will be studied through 3 phases lasting a total of 4 weeks: Phase 1: administration of study medication at the end of hemodialysis treatment. Phase 2: no administration of study medication. Phase 3: administration of study medication at the beginning of hemodialysis.
Dosage Form: Intravenous administration. Dosage: 0.01 micrograms/kilogram of body weight. Frequency: 2 HD treatments of each study week (depending on phase of study). Duration: 4 weeks.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Irving Place Dialysis Center
New York, New York, 10003, United States
Upper Manhattan Dialysis Center
New York, New York, 10025, United States
Yorkville Dialysis Center
New York, New York, 10128, United States
Nathan W Levin, MD
Renal Research Institute
20 participants (actual enrollment reported by the registry).
First Submitted
May 27, 2008
First Posted
May 30, 2008
Study Start
December 2004
Date type not reportedThis date has not been verified as actual or estimated.
The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors
Salt Intake and Antiproteinuric Effect of Paricalcitol in Type 2 Diabetes
Contact the study team to confirm eligibility.
Primary Completion
September 2007
Actual (reported)Study Completion
September 2007
Actual (reported)Last Updated
May 13, 2009
Record last verified: 2009-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: